Cluster composition

Functions

CategoryNameIntersectionWithQueryPValueGenesInTermGenesInQueryGenesInTermInQueryID
GeneOntologyMolecularFunctionprotein kinase activator activity

STK4 CAB39 MOB3B CAB39L

5.30e-05149284GO:0030295
GeneOntologyMolecularFunctionkinase activator activity

STK4 CAB39 MOB3B CAB39L

6.83e-05159284GO:0019209
GeneOntologyMolecularFunctionprotein serine/threonine kinase activator activity

STK4 CAB39 CAB39L

1.75e-0478283GO:0043539
GeneOntologyMolecularFunctionprotein kinase regulator activity

STK4 CAB39 MOB3B CAB39L

4.43e-04259284GO:0019887
GeneOntologyMolecularFunctionkinase regulator activity

STK4 CAB39 MOB3B CAB39L

8.18e-04305284GO:0019207
GeneOntologyMolecularFunctionenzyme regulator activity

STK4 CAB39 MOB3B CAB39L PPP1R12A DOCK9 NUCB1

2.82e-031418287GO:0030234
GeneOntologyMolecularFunctionnuclear receptor coactivator activity

ACTN2 PPRC1

3.30e-0361282GO:0030374
DomainMo25

CAB39 CAB39L

2.17e-062282IPR013878
DomainMo25

CAB39 CAB39L

2.17e-062282PF08569
DomainARM-type_fold

CAB39 NCAPD3 CAB39L ODAD2 MTOR DOCK9

9.20e-06339286IPR016024
Domain-

CAB39 NCAPD3 CAB39L ODAD2 MTOR

1.78e-052222851.25.10.10
DomainARM-like

CAB39 NCAPD3 CAB39L ODAD2 MTOR

4.55e-05270285IPR011989
DomainHEAT

NCAPD3 ODAD2 MTOR

8.81e-0558283IPR000357
DomainHEAT_REPEAT

NCAPD3 ODAD2 MTOR

1.54e-0470283PS50077
PathwayREACTOME_ENERGY_DEPENDENT_REGULATION_OF_MTOR_BY_LKB1_AMPK

CAB39 CAB39L MTOR

7.42e-0629193M19861
PathwayREACTOME_ENERGY_DEPENDENT_REGULATION_OF_MTOR_BY_LKB1_AMPK

CAB39 CAB39L MTOR

7.42e-0629193MM14980
PathwayREACTOME_MTOR_SIGNALLING

CAB39 CAB39L MTOR

2.14e-0541193M27000
PathwayREACTOME_MTOR_SIGNALLING

CAB39 CAB39L MTOR

2.31e-0542193MM14638
PathwayKEGG_MTOR_SIGNALING_PATHWAY

CAB39 CAB39L MTOR

4.40e-0552193M7561
Pubmed

Mst1 regulates glioma cell proliferation via the AKT/mTOR signaling pathway.

STK4 MTOR

1.87e-06328225373346
Pubmed

Threonine-120 phosphorylation regulated by phosphoinositide-3-kinase/Akt and mammalian target of rapamycin pathway signaling limits the antitumor activity of mammalian sterile 20-like kinase 1.

STK4 MTOR

3.75e-06428222619175
Pubmed

Hippo/Mst signalling couples metabolic state and immune function of CD8α+ dendritic cells.

STK4 MTOR

3.42e-051128229849151
Pubmed

ESCPE-1 mediates retrograde endosomal sorting of the SARS-CoV-2 host factor Neuropilin-1.

PON2 MYOF NCAPD3 NAT14 R3HDM1 KIAA2013 NUCB1

3.60e-05120128735696571
Pubmed

Automated immobilized metal affinity chromatography/nano-liquid chromatography/electrospray ionization mass spectrometry platform for profiling protein phosphorylation sites.

R3HDM1 PPP1R12A

5.65e-051428215570572
Pubmed

Deletion of Sarcolemmal Membrane-Associated Protein Isoform 3 (SLMAP3) in Cardiac Progenitors Delays Embryonic Growth of Myocardium without Affecting Hippo Pathway.

STK4 MTOR

6.52e-051528238474134
Pubmed

An FAK-YAP-mTOR Signaling Axis Regulates Stem Cell-Based Tissue Renewal in Mice.

STK4 MTOR

6.52e-051528228457749
Pubmed

AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism.

CAB39 CAB39L

9.49e-051828216054041
Pubmed

A microRNA-Hippo pathway that promotes cardiomyocyte proliferation and cardiac regeneration in mice.

STK4 ACTN2

1.06e-041928225787764
Pubmed

Prediction of the coding sequences of mouse homologues of KIAA gene: II. The complete nucleotide sequences of 400 mouse KIAA-homologous cDNAs identified by screening of terminal sequences of cDNA clones randomly sampled from size-fractionated libraries.

R3HDM1 PPRC1 PHF3 DOCK9

3.03e-0440728412693553
Pubmed

Network organization of the human autophagy system.

STK4 CAB39 CAB39L MTOR

3.96e-0443728420562859
Pubmed

DNA Repair Network Analysis Reveals Shieldin as a Key Regulator of NHEJ and PARP Inhibitor Sensitivity.

PON2 NCAPD3 NAT14 PHF3

4.54e-0445328429656893
Pubmed

Global landscape of HIV-human protein complexes.

PON2 NCAPD3 PPP1R12A KIAA2013

4.69e-0445728422190034
Pubmed

A central chaperone-like role for 14-3-3 proteins in human cells.

STK4 R3HDM1 MTOR PHF3 PPP1R12A

5.63e-0486128536931259
Pubmed

LRRC31 inhibits DNA repair and sensitizes breast cancer brain metastasis to radiation therapy.

MYOF NCAPD3 MTOR

5.68e-0420228333005030
Pubmed

Prediction of the coding sequences of mouse homologues of KIAA gene: IV. The complete nucleotide sequences of 500 mouse KIAA-homologous cDNAs identified by screening of terminal sequences of cDNA clones randomly sampled from size-fractionated libraries.

MYOF AARS2 TMEM200A KIAA2013

6.23e-0449328415368895
Pubmed

Construction of expression-ready cDNA clones for KIAA genes: manual curation of 330 KIAA cDNA clones.

MYOF PHF3 DOCK9

7.77e-0422528312168954
CytobandEnsembl 112 genes in cytogenetic band chr6q23

MTFR2 TMEM200A

2.41e-03119282chr6q23
GeneFamilyArmadillo repeat containing|Protein phosphatase 1 regulatory subunits

TSKS PPP1R12A

9.61e-03181152694
CoexpressionFAN_EMBRYONIC_CTX_BIG_GROUPS_EXCITATORY_NEURON

ACTN2 R3HDM1 ADCY1 DOCK9

1.80e-0747284M39019
CoexpressionGSE27896_HDAC6_KO_VS_WT_TREG_UP

STK4 MYOF PPRC1 ADCY1

3.55e-05176284M8248
ToppCellsaliva-Severe-critical_progression_d28-40-Epithelial-Epithelial,_Airway-secretory_cell|Severe-critical_progression_d28-40 / Compartment, severity and other cell annotations on 10x 3' data (130k)

PON2 MYOF PPRC1 TMEM200A

6.72e-06197284d6c9da7a3a6d2bcb13e2fc6605c8a59e7fb121c5
ToppCellsaliva-Severe-critical_progression_d28-40-Epithelial-Epithelial,_Airway-secretory_cell-Epi-Secretory|Severe-critical_progression_d28-40 / Compartment, severity and other cell annotations on 10x 3' data (130k)

PON2 MYOF PPRC1 TMEM200A

6.72e-0619728480b05c8ad9c1edc5dea3236079372475431343fe
ToppCellNeuron-Postmitotic-Excitatory_Neuron_-Upper_Layer|World / Primary Cells by Cluster

ACTN2 R3HDM1 ADCY1 DOCK9

7.14e-06200284db10f76938af553d1a2275bb02ef75dff3c3135b
ToppCellFetal_brain-fetalBrain_Zhong_nature-GW26|fetalBrain_Zhong_nature / Sample Type, Dataset, Time_group, and Cell type.

ACTN2 R3HDM1 ADCY1 DOCK9

7.14e-0620028461d7dd0a78942b069c3f5e75044368dc00e6e8e6
ToppCellNeuron-Postmitotic-Excitatory_Neuron_-Upper_Layer-21|World / Primary Cells by Cluster

ACTN2 R3HDM1 ADCY1 DOCK9

7.14e-0620028430a3e4aee12ec1b5acdce90f86c9733c27a7f6fc
ToppCellFetal_brain-organoid_Tanaka_cellReport-GW26|organoid_Tanaka_cellReport / Sample Type, Dataset, Time_group, and Cell type.

ACTN2 R3HDM1 ADCY1 DOCK9

7.14e-062002845c7263c862093ad9dbc81d06b16b6f74e8a6b634
ToppCellfacs-Lung-Endomucin-3m-Lymphocytic-CD4+_T|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation

NAT14 ACTN2 FAM149B1

1.35e-041602835c68d6a76c59e3a7e668ae5471396478a55756ac
ToppCellfacs-Lung-Endomucin-3m-Lymphocytic-CD4-positive,_alpha-beta_T_cell|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation

NAT14 ACTN2 FAM149B1

1.35e-041602830fee84844733d36805e1df90ca09478169746708
ToppCell343B-Myeloid-Macrophage-FABP4+_Macrophage_proliferating_2|343B / Donor, Lineage, Cell class and subclass (all cells)

NCAPD3 MTFR2 TSKS

1.54e-041672837efa0081e79f22b219eac64ffcaedb2179cde299
ToppCellBAL-Severe-Myeloid-cDC-cDC-cDC_4|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09)

PON2 MOB3B KCTD3

1.56e-04168283d60f7cd8269f373827f49c7785002cb38e4570a9
ToppCellBAL-Severe-Myeloid-cDC-cDC-cDC_4|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)

PON2 MOB3B KCTD3

1.59e-04169283ccd98f9005aa0a88bd49f153be4e7200cc3dd0ac
ToppCellPBMC_fresh-frozen-Severe-critical_progression_d12-22_with-steroid-Lymphocytic-Lymphocytic_T-mature_alpha-beta_T_cell-T_CD4_c04-ANXA2|Severe-critical_progression_d12-22_with-steroid / Compartment, severity and other cell annotations on 10x 3' data (130k)

MTFR2 TSKS TMEM200A

1.76e-041752835f5fc1bf29f07e086951d4f9486b5f07bdcc5d4f
ToppCellTCGA-Lung-Primary_Tumor-Lung_Carcinoma-Lung_Adenocarcinoma_Mixed_Subtype-4|TCGA-Lung / Sample_Type by Project: Shred V9

PON2 CAB39 MYOF

1.79e-041762830923b01137d6f9956ca815b41102c81e82624065
ToppCellrenal_cortex_nuclei-Hypertensive_with+without-CKD-Epithelial-Renal_corpuscle_epithelial_cell-parietal_epithelial_cell-Parietal_Epithelial_Cell|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group

MYOF ODAD2 BICD1

2.18e-04188283874404a4fd9aa42873f6c53dc42da22d3b0fdb9e
ToppCellrenal_cortex_nuclei-Hypertensive_with+without-CKD-Epithelial-Renal_corpuscle_epithelial_cell-parietal_epithelial_cell|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group

MYOF ODAD2 BICD1

2.18e-04188283b21e93a70583c30d05c0833cd3d4d4bca44a039e
ToppCellLA-13._Vascular_Smooth_Muscle|World / Chamber and Cluster_Paper

MYOF TMEM200A PPP1R12A

2.21e-041892836b3e88751b95fc2173f2c3d5061ed632d0c5f01c
ToppCellfacs-Skin-Anagen-3m-Epithelial|Skin / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation

CAB39 MYOF ADCY1

2.25e-04190283888ded899f0513d41bf655896d59ae8ef74e0978
ToppCellfacs-Skin-Anagen-3m|Skin / Skin_Bladder_Kidney_Mammary_Gland - method, tissue, subtissue, age, lineage, cell ontology and free annotation

CAB39 MYOF ADCY1

2.25e-041902833466cebab16964e94da130d0673fa32e7d90b5ed
ToppCellrenal_cortex_nuclei-CKD+DKD_normotensive|renal_cortex_nuclei / Celltypes from Cells and Nuclei per compartment and clinical group

CAB39 MYOF PPRC1

2.32e-041922838b86db2ebe0199fee0e9800566a619a24bfdeed5
ToppCellControl-Endothelial-Endothelial-Gen_Cap|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

STK4 DOCK9 BICD1

2.35e-04193283e1d546165dcc2392f540162206852c4717d7306f
ToppCellLPS-IL1RA-Endothelial-Endothelial-Gen_Cap|LPS-IL1RA / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

STK4 DOCK9 BICD1

2.39e-041942830b9cd96fa0b616da7cc90e92ff71157e9bba518f
ToppCellCOVID-19_Severe-PLT_4|World / Disease Group and Platelet Clusters

CCDC174 PHF3 PPP1R12A

2.46e-04196283ad43efdd4d73b6615f65f06a315b33576e317473
ToppCellBrain_organoid-organoid_Velasco_nature-6_mon-Neuronal-CPNs|6_mon / Sample Type, Dataset, Time_group, and Cell type.

R3HDM1 ADCY1 DOCK9

2.46e-04196283c9e7ac34993c873de4f198cdae77dcf099731532
ToppCellTracheal-10x3prime_v2-Stromal-Fibroblastic-Fibro_immune_recruiting|10x3prime_v2 / Cell types per location group and 10X technology with lineage, and cell group designations

MOB3B PPRC1 TMEM200A

2.50e-041972834edf043e8f586fd375f56485841fe992a18bf853
ToppCellBronchial-NucSeq-Stromal-Schwann-Schwann_nonmyelinating|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations

CAB39L ADCY1 KCTD3

2.50e-041972834a7ff67bb0754e034e6f2a1bd34cde86ee3ef899
ToppCellBAL-Control-Myeloid-TRAM-TRAM2-|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)

PON2 MYOF NUCB1

2.57e-04199283b8dc5dc9fe3f52be11940d45959134b2a7575a8b
ToppCellBAL-Control-Myeloid-TRAM-TRAM2-|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.09)

PON2 MYOF NUCB1

2.57e-04199283bbf81fb20da8a28aac024207696c6ea00473a0df
ToppCellBAL-Control-Myeloid-TRAM-TRAM2|Control / Location, Disease Group, Cell group, Cell class (2021.03.09)

PON2 MYOF NUCB1

2.57e-0419928390b20fce27739f28609d664475a197eea586e030
ToppCellTransverse-Macrophage-LYVE1_Macrophage|Macrophage / Region, Cell class and subclass

MYOF MTOR DOCK9

2.57e-04199283fd75dccb37d96448edf72b7d042b06833d4ead24
ToppCellBAL-Control-Myeloid-TRAM-TRAM2|Control / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)

PON2 MYOF NUCB1

2.57e-04199283617fd53c799722879acd8f2fd69b331d82e7bdb9
ToppCellControl-Myeloid-TRAM2|Control / Disease group,lineage and cell class （2021.01.30）

PON2 MYOF NUCB1

2.57e-041992835a08184573e524ce0e2974eed9817354890830a9
ToppCellFetal_brain-fetalBrain_Zhong_nature-GW26-Neuronal-GABAergic_neurons|GW26 / Sample Type, Dataset, Time_group, and Cell type.

R3HDM1 ADCY1 DOCK9

2.61e-04200283bad32a95b759fad509401b07bc96a56687c2a592
ToppCellsevere-cDC|severe / Cohort 1 (10x PBMC) with disease condition, cell group and cell class

PON2 MOB3B MYOF

2.61e-0420028326e04ea276dbca5cde48335c401269c7123b54d2
ToppCellNeuron-Postmitotic-Excitatory_Neuron_-Upper_Layer_Occipital|World / Primary Cells by Cluster

ACTN2 R3HDM1 ADCY1

2.61e-042002836bbe8e1f3e91678f1bfb14945365c1578a59a604
ToppCellNeuron-Postmitotic-Excitatory_Neuron_-Upper_Layer_Occipital-19|World / Primary Cells by Cluster

ACTN2 R3HDM1 ADCY1

2.61e-04200283c831d9e0a7178e3634da45548f91fa9e8dc6557c
DrugPiperidolate hydrochloride [129-77-1]; Up 200; 11.2uM; MCF7; HT_HG-U133A

MOB3B MYOF ACTN2 FAM149B1 R3HDM1 DOCK9

1.25e-071972863551_UP
DrugHydrocotarnine hydrobromide [5985-00-2]; Up 200; 13.2uM; HL60; HG-U133A

PON2 MOB3B ACTN2 PPRC1 BICD1 NUCB1

1.29e-071982861772_UP
Drugethylmethylamine

ADCY1 PPP1R12A NUCB1

2.95e-0549283CID000012219
DrugMepenzolate bromide [76-90-4]; Down 200; 9.6uM; PC3; HT_HG-U133A

STK4 R3HDM1 PHF3 BICD1

8.06e-051892844304_DN
DrugPromazine hydrochloride [53-60-1]; Up 200; 12.4uM; PC3; HT_HG-U133A

ACTN2 FAM149B1 DOCK9 NUCB1

8.06e-051892844308_UP
DrugTiratricol, 3,3',5-triiodothyroacetic acid [51-24-1]; Down 200; 6.4uM; HL60; HG-U133A

ACTN2 PHF3 BICD1 KCTD3

8.74e-051932841412_DN
DrugH-89, Dihydrochloride; Up 200; 0.5uM; PC3; HT_HG-U133A

MYOF MTOR PHF3 BICD1

8.91e-051942846921_UP
DrugTetrahydroxy-1,4-quinone monohydrate [319-89-1]; Down 200; 21uM; MCF7; HT_HG-U133A

STK4 MYOF ACTN2 PPP1R12A

8.91e-051942844159_DN
DrugFamprofazone [22881-35-2]; Down 200; 10.6uM; PC3; HT_HG-U133A

STK4 R3HDM1 PHF3 PPP1R12A

8.91e-051942844309_DN
DrugFlunisolide [3385-03-3]; Down 200; 9.2uM; MCF7; HT_HG-U133A

MOB3B MYOF BICD1 NUCB1

9.09e-051952843923_DN
DrugKawain [500-64-1]; Up 200; 17.4uM; PC3; HT_HG-U133A

STK4 R3HDM1 PHF3 DOCK9

9.28e-051962847369_UP
DrugCanavanine sulfate monohydrate (L,+) [206996-57-8]; Down 200; 13.6uM; MCF7; HT_HG-U133A

STK4 FAM149B1 PPP1R12A DOCK9

9.28e-051962844782_DN
DrugAntipyrine, 4-hydroxy [1672-63-5]; Up 200; 19.6uM; MCF7; HT_HG-U133A

STK4 MYOF ACTN2 BICD1

9.28e-051962841497_UP
DrugAmpyrone [83-07-8]; Down 200; 19.6uM; MCF7; HT_HG-U133A

STK4 MYOF ACTN2 PHF3

9.28e-051962842249_DN
Drugestradiol, USP; Down 200; 0.1uM; PC3; HT_HG-U133A

MOB3B MYOF PPRC1 PHF3

9.46e-051972841208_DN
DrugRoxithromycin [80214-83-1]; Down 200; 4.8uM; HL60; HT_HG-U133A

STK4 MYOF R3HDM1 BICD1

9.46e-051972842992_DN
DrugClofilium tosylate [92953-10-1]; Up 200; 7.8uM; MCF7; HT_HG-U133A

ACTN2 R3HDM1 PHF3 DOCK9

9.46e-051972843187_UP
DrugIsoxicam [34552-84-6]; Down 200; 12uM; MCF7; HT_HG-U133A

FAM149B1 MTOR PHF3 NUCB1

9.65e-051982847028_DN
DrugScopolamin-N-oxide hydrobromide [6106-81-6]; Down 200; 10uM; HL60; HG-U133A

PON2 MOB3B PPP1R12A KCTD3

9.65e-051982841415_DN
Drugfluphenazine dihydrochloride; Down 200; 10uM; PC3; HT_HG-U133A

MOB3B PPRC1 MTOR ADCY1

9.65e-051982841237_DN
DrugFursultiamine Hydrochloride [2105-43-3]; Up 200; 9.2uM; PC3; HT_HG-U133A

ACTN2 TSKS PHF3 BICD1

9.65e-051982846630_UP
DrugHeptaminol hydrochloride [543-15-7]; Down 200; 22uM; PC3; HT_HG-U133A

MYOF PHF3 BICD1 NUCB1

9.65e-051982841825_DN
DrugKhellin [82-02-0]; Up 200; 15.4uM; HL60; HG-U133A

STK4 MOB3B PHF3 KCTD3

9.84e-051992842004_UP
DrugNatamycin [7681-93-8]; Down 200; 6uM; HL60; HT_HG-U133A

MYOF FAM149B1 R3HDM1 BICD1

9.84e-051992846126_DN
DrugMeropenem [96036-03-2]; Down 200; 10.4uM; MCF7; HT_HG-U133A

FAM149B1 PHF3 BICD1 NUCB1

9.84e-051992843564_DN
DrugAltretamine [654-05-6]; Up 200; 19uM; MCF7; HT_HG-U133A

MOB3B FAM149B1 TSKS DOCK9

9.84e-051992845688_UP
DrugTestosterone propionate [57-85-2]; Down 200; 11.6uM; HL60; HT_HG-U133A

PON2 MYOF PHF3 NUCB1

9.84e-051992841295_DN
DrugFelbinac [5728-52-9]; Down 200; 18.8uM; PC3; HT_HG-U133A

STK4 MOB3B ADCY1 DOCK9

1.00e-042002844639_DN
DrugSuramin sodium salt; Up 200; 10uM; PC3; HT_HG-U133A

MOB3B R3HDM1 ADCY1 PHF3

1.00e-042002847501_UP
Drugaspirin, USP; Down 200; 100uM; HL60; HT_HG-U133A

MYOF TSKS PHF3 BICD1

1.00e-042002842664_DN
Drugtripyridyltriazine

PON2 MTOR

1.13e-0413282CID000077258
Drugthiadiazolidinone

PPRC1 MTOR

1.32e-0414282CID000443041
Diseasecancer (implicated_via_orthology)

STK4 CAB39 CAB39L MTOR

9.91e-05268274DOID:162 (implicated_via_orthology)
Diseaseresponse to platinum based chemotherapy

ODAD2 ADCY1

1.22e-0418272EFO_0004647
DiseaseEpileptic encephalopathy

MTOR KCTD3

3.45e-0430272C0543888
Diseasebirth weight, pelvic organ prolapse

CAB39 DOCK9

9.23e-0449272EFO_0004344, EFO_0004710

Protein segments in the cluster

PeptideGeneStartEntry
KPENLKLMMNLLRDK

CAB39L

251

Q9H9S4
MEIAEKHLDIPKMLD

ACTN2

216

P35609
PMIDKDKEALMEEIL

BICD1

661

Q96G01
SKPENLKLMMNLLRD

CAB39

251

Q9Y376
LKNNPRDRMMLLKLE

R3HDM1

161

Q15032
MNLIDRKELEPLKEM

MOB3B

196

Q86TA1
MREDEKPLVLEMLKA

NAT14

11

Q8WUY8
LRMLLKAKMDAEQDP

NUCB1

111

Q02818
LMMDLKEEKPRAREL

PON2

86

Q15165
LPRNVAMEMKEDFLK

ADCY1

271

Q08828
DMLKLLADFRKPEKM

DOCK9

561

Q9BZ29
MRKDLPDLLEMDKNL

CCDC174

176

Q6PII3
DMQKFPLRMKDNDLL

KCTD3

341

Q9Y597
PSLRDKDLEMEELML

PPRC1

71

Q5VV67
LMDKLLDLDDKLLMR

FAM149B1

371

Q96BN6
KMDTNKDDPELMLGR

MTOR

1466

P42345
MKLENKEDPMDRLLV

TMEM200A

431

Q86VY9
DDPESEIKMKIAMLL

ODAD2

161

Q5T2S8
DDIALQMEKMLFPLK

SPATA31E1

36

Q6ZUB1
LGLPLDMVELMLEEK

AARS2

446

Q5JTZ9
LLAMRSKPDKDLLME

NCAPD3

1156

P42695
LEDSLKNMLSDKDPM

PHF3

41

Q92576
NLLLTDKMKPEEKMA

TSKS

531

Q9UJT2
RNKDIPNMLDVLKDM

MTFR2

266

Q6P444
VEDLQKRLLALDPMM

STK4

441

Q13043
KRLLALDPMMEQEIE

STK4

446

Q13043
RKEMLELLDMPAAEL

KIAA2013

316

Q8IYS2
PEKCRLDMIPDLKAM

MYOF

1916

Q9NZM1
EMEEELKMLPDLKAD

PPP1R12A

996

O14974